BMS will file for earlier-line use of Breyanzi in lymphoma after trial winBristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but Share XBMS will file for earlier-line use of Breyanzi in lymphoma after trial winhttps://pharmaphorum.com/news/bms-will-file-for-earlier-line-use-of-breyanzi-in-lymphoma-after-trial-win/
BMS finally gets FDA OK for liso-cel, sets $410k launch priceBristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US Share XBMS finally gets FDA OK for liso-cel, sets $410k launch pricehttps://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/
